Daniel Cressy, 23, has become the first person in Louisiana to achieve a functional sickle cell cure through groundbreaking gene therapy at New Orleans’ Manning Family Children’s Hospital, reigniting his dream of becoming a pilot

In New Orleans, Louisiana, on Monday 22 June 2026, 23-year-old Daniel Cressy from Metairie became the first person in the state to achieve a functional sickle cell cure after undergoing gene therapy at Manning Family Children’s Hospital.

The aspiring pilot had long faced the painful and unpredictable effects of the inherited blood disorder, which severely limited his ability to pursue aviation.

Doctors confirmed that the disease is no longer active in his system following the innovative treatment.

This remarkable milestone comes after a demanding two-year journey that included extracting his own stem cells, editing them in a laboratory to prevent the production of defective sickle-shaped cells, and infusing the corrected cells back into his body.

The therapy, known as Casgevy, harnesses CRISPR technology to boost foetal haemoglobin production, offering a transformative one-time intervention.

Louisiana bears one of the highest burdens of sickle cell disease in the United States, with around 3,000 diagnosed individuals and roughly 80 newborns identified each year.

Historically, patients have relied on lifelong symptom management, but recent advances in gene therapy are bringing genuine hope for a lasting solution, particularly in the Gulf South region.

Daniel Cressy reflected on the profound personal toll, stating, “This entire journey was the hardest thing I’ve been in my life, and the reason why I worked so hard with our organisation, Privileged Pilots, is because I don’t want anybody else to have to experience the loneliness and the uncertainty and the hopelessness that I felt a couple of years ago.”

He added, “Someone’s ability to access treatment and potentially cure should not be defined by their zip code.”

The treatment process proved arduous, involving intensive chemotherapy and weeks of hospital isolation, yet the outcome has been profoundly encouraging.

Medical teams at the hospital, Louisiana’s sole centre offering this therapy, celebrated as Daniel Cressy rang the ceremonial bell, symbolising his victorious transition to a healthier future.

This pioneering success not only restores Daniel Cressy’s long-cherished dream of soaring as a commercial pilot but also inspires broader efforts to expand access.

He now plans to channel his experience into a nonprofit aimed at supporting others navigating similar challenges, emphasising equity in care across communities.

While the high cost of such therapies, often exceeding two million dollars, presents ongoing hurdles for wider adoption, this breakthrough represents a powerful stride in medical innovation and human resilience against a condition that has affected families for generations.